西班牙移植中心供者细胞来源血液肿瘤的分子机制与患病率
分子分析显示生殖系易感性是主要机制,支持移植前对原发病患者进行生殖系评估并对相关供者做级联筛查。
要点
- DDHN患病率0.28%,亲属供者移植后显著高于无关供者(0.41% vs 0.06%)。
- 中位潜伏期56个月,以髓系肿瘤为主,MDS占51%、AML占36%。
- 生殖系致病/可能致病变异见于10例,以DDX41(n=7)最常见。
核心结论
- 遗传性生殖系易感性可能是亲属异基因移植后DDHN的主要分子驱动因素。
研究设计与样本
- DDHN诊断需细胞遗传学或分子学确认供者来源。
- 分子研究包括生殖系增强的靶向NGS、全外显子测序及供受者比较分析。
主要发现
- 2007至2025年共识别39例DDHN。
- 2013-2022年8465例异基因移植中DDHN患病率为0.28%。
- 亲属供者移植后DDHN患病率0.41%,无关供者0.06%(p=0.0026)。
- 移植至DDHN诊断的中位潜伏期为56个月。
- DDHN以髓系肿瘤为主,MDS占51%、AML占36%。
关键数值与推荐
- 33例可进行分子分析,10例检出致病/可能致病生殖系变异。
- 生殖系变异涉及DDX41(n=7)、CEBPA(n=2)和CHEK2(n=1),均发生于亲属供者移植后。
- DDX41相关DDHN显示复发性体细胞打击和低基因组复杂性。
- 仅1例髓系病例确认供者来源克隆性造血,涉及U2AF1。
临床怎么用
- 建议在原发病诊断时、移植前对患者进行全面的生殖系评估。
- 对候选亲属供者进行针对性的级联筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Donor cell-derived hematologic neoplasm (DDHN) is defined as a de novo hematologic malignancy originated from transplanted donor stem cells, distinct from the original recipient's disease (ORD). Its prevalence and biological mechanisms remain poorly defined. We conducted a nationwide study to estimate the prevalence of DDHN and characterize its clinical and molecular features. Twenty-four transplantation centers systematically reviewed their allogeneic hematopoietic stem cell transplantation (allo-HSCT) cohorts. DDHN diagnosis required cytogenetic or molecular donor-origin confirmation. Molecular studies included germline-augmented targeted NGS, whole-exome sequencing, and donor-recipient comparative analyses. We identified 39 DDHN cases diagnosed between 2007 and 2025. Among 8,465 allo-HSCT performed between 2013-2022, DDHN prevalence was 0.28%, with a marked predominance after related-donor compared with unrelated transplantation (0.41% vs. 0.06%, p=0.0026). Median latency from transplantation to DDHN diagnosis was 56 months. Most DDHN were myeloid neoplasms, predominantly myelodysplastic neoplasms (51%) and acute myeloid leukemia (36%). Molecular characterization, available in 33 cases, revealed germline predisposition as the predominant underlying mechanism. Pathogenic/likely pathogenic germline variants were identified in 10 cases, involving DDX41 (n=7), CEBPA (n=2), and CHEK2 (n=1), all after a related-donor transplantation. DDX41-associated DDHN showed recurrent somatic hits and low genomic complexity. Donor-derived clonal hematopoiesis was confirmed in only one myeloid case involving U2AF1. These findings support inherited germline predisposition as the potential main molecular driver of DDHN after related allo-HSCT, reinforcing the recommendation for comprehensive germline evaluation of patients at ORD diagnosis prior to transplantation, followed by targeted cascade screening of candidate related donors.
引用
- Gabarros-Subira M, Pomares H, Beas F, et al. Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers. Blood. 2026. PMID: 42932250. doi:10.1182/blood.2026035181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。